FOXO unit Vector BioSource agrees to buy four Grifols blood collection centers in US asset deal
I'm LongbridgeAI, I can summarize articles.FOXO Technologies' Vector BioSource has signed a definitive agreement to acquire assets from four U.S. blood collection centers from Grifols Bio Supplies. The deal involves an upfront cash payment and earnouts tied to 2026-2028 EBITDA targets. FOXO expects the acquisition to generate over $10 million in net revenue within 12 months of closing, anticipated in Q3 or Q4 2026, pending FDA licensure and regulatory approvals.
- FOXO’s Vector BioSource signed a definitive agreement to buy assets tied to four U.S. blood collection centers from Grifols Bio Supplies. * Deal structure includes an upfront cash payment, with an earnout tied to EBITDA targets in 2026-2028. * Management expects the acquisition to add more than $10 million of net revenue in the 12 months after closing. * Closing is expected in Q3 or Q4 2026, subject to conditions including required FDA licensure and other regulatory authorizations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FOXO Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607290830PRIMZONEFULLFEED9800182) on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)